Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization

Journal of Pharmacological and Toxicological Methods

Volumn 49, Issue 3, 2004, Pages 159-169

  Guth, Brian D ^a   Germeyer, Sabine ^a   Kolb, Willi ^a   Markert, Michael ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Action potential; Arrhythmia; Electrocardiogram; hERG channels; Methods; Preclinical models; QT prolongation; Torsades de pointes

Indexed keywords

ACETYLSALICYLIC ACID; ASTEMIZOLE; BEPRIDIL; CISAPRIDE; COCAINE; DOFETILIDE; DOXORUBICIN; ERYTHROMYCIN; GUANIDINE; NIFEDIPINE; POTASSIUM CHANNEL HERG; SALMETEROL; SIBUTRAMINE; SOTALOL; SUMATRIPTAN; TERFENADINE; VERAPAMIL;

ACTION POTENTIAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; HEART REPOLARIZATION; HUMAN; IC 50; META ANALYSIS; NONHUMAN; REVIEW; RISK ASSESSMENT;

EID: 2542432906     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2004.02.006     Document Type: Article

References (27)

1. Bachmann A., Mueller S., Kopp K., Brueggemann A., Suessbrich H., Gerlach U., Busch A.E. Inhibition of cardiac potassium currents by pentobarbital. Naunyn-Schmiedeberg's Archives of Pharmacology. 365:2002;29-37
2. Batey A.J., Doe C.P.A. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs. Journal of Pharmacological and Toxicological Methods. 5408:2003;1-9
3. Champeroux P., Martel E., Vannier C., Blanc V., Leguennec J.-Y., Fowler J., Richard S. The preclinical assessment of the risk for QT interval prolongation. Thérapie. 55:2000;101-109
4. CPMP: Committee for Proprietary Medicinal Products The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, CPMP 986/96. 1997;European Agency for the Evaluation of Medicinal Products, London
5. Crumb W., Cavero I. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development. Pharmaceutical Science and Technology Today. 2(7):1999;270-280
6. Davis A.S. The pre-clinical assessment of QT interval prolongation: A comparison to in vitro and in vivo models. Human and Experimental Toxicology. 17:1998;677-680
7. DePonti F., Poluzzi E., Montanaro N. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. European Journal of Clinical Pharmacology. 56:2000;1-18
8. Gintant G.A., Limeris J.T., McDermott J.S., Wegner C.D., Cox B.F. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. Journal of Cardiovascular Pharmacology. 37:2001;607-618
9. Gralinski M.R. The assessment of potential for QT interval prolongation with new pharmaceuticals. Impact on drug development. Journal of Pharmacological and Toxicological Methods. 43:2000;91-99
10. Guidance for industry. S7a safety pharmacology studies for human pharmaceuticals. 2001, July;U.S. Department of Health and Human Services, Food and Drug administration. www.fda.gov/cber/guidelines.htm; ICH
11. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., Escande D., Franz M., Malik M., Moss A., Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Cardiovascular Research. 47:2000;219-233
12. Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation. 103:2001;2004-2013
13. Kinter L.B., Valentin J.-P. Safety pharmacology and risk assessment. Fundamental and Clinical Pharmacology. 16:2002;175-182
14. Li J., Correa A.M. Kinetic modulation of HERG potassium channels by the volatile anesthetic halothane. Anesthesiology. 97:2002;921-930
15. Malik M., Camm A.J. Evaluation of drug-induced QT interval prolongation. Implications for drug approval and labelling. Drug Safety. 24(5):2001;323-351
16. Mizazaki, H., Kitayama, T., Tashibut, H., Ando, K., Yamamoto, K., Sagami, F. (2003, September). JPMA QT PRODACT: Comparison of the sensitivity between canine telemetry assay and isoflurane-anesthetized model. Abstract Presented at the Safety Pharmacology Society meeting. Noordwyk, the Netherlands, 2003 September.
17. Netzer R., Ebnether A., Bischoff U., Pongs O. Screening lead compounds for QT interval prolongation. Drug Discovery Today. 6(2):2001;78-84
18. Pourrias B., Porsolt R.D., Lacroix P. QT interval prolongation by noncardiovascular drugs: A proposed assessment strategy. Drug Development Research. 47:1999;55-62
19. Raunig D., DePasquale M.J., Huang C., Winslow R., Fossa A.A. Statistical analysis of QT interval as a function of changes in RR interval in the conscious dog. Journal of Pharmacology and Toxicological Methods. 46:2001;1-11
20. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K.S., Strang I., Sullivan A.T., Wallis R., Camm A.J., Hammond T.G. Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisitional safety margin in drug development. Cardiovascular Research. 58:2003;32-45
21. Sarma J.S.M., Sarma R.J., Bilitch M., Katz D., Song S. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: Re-evaluation of Bazett's formula. American Heart Journal. 54:1984;103-108
22. Shimizu W., McMahon B., Antzelevitch C. Sodium pentobarbital reduced transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndrome. Journal of Cardiovascular Electrophysiology. 10(2):1999;154-164
23. Vandenberg J.I., Walker B.D., Campbell T.J. HERG K+ channels: Friend and foe. Trends in Pharmacological Sciences. 22:2001;240-246
24. Webster R., Leischman D., Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Current Opinion in Drug Discovery and Development. 5(1):2002;116-126
25. Witchel H.J., Milnes J.T., Mitcheson J.S., Hancox J.C. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. Journal of Pharmacological and Toxicological Methods. 48:2002;65-80
26. Yan G.-X., Shimizu W., Antzelevitch C. Characteristics and distribution of M-cells in arterially perfused canine left ventricular wedge preparations. Circulation. 98:1998;1921-1927
27. Kr: Model systems and relevance to human arrhythmias. Journal of Cardiovascular Pharmacology. 38:2001;737-744